<SEC-DOCUMENT>0001104659-24-113659.txt : 20241104
<SEC-HEADER>0001104659-24-113659.hdr.sgml : 20241104
<ACCEPTANCE-DATETIME>20241104073014
ACCESSION NUMBER:		0001104659-24-113659
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241104
DATE AS OF CHANGE:		20241104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Journey Medical Corp
		CENTRAL INDEX KEY:			0001867066
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				471879539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41063
		FILM NUMBER:		241420756

	BUSINESS ADDRESS:	
		STREET 1:		9237 E VIA DE VENTURA BLVD., SUITE 105
		CITY:			SCOTTSDALE
		STATE:			AZ
		ZIP:			85258
		BUSINESS PHONE:		480-434-6670

	MAIL ADDRESS:	
		STREET 1:		9237 E VIA DE VENTURA BLVD., SUITE 105
		CITY:			SCOTTSDALE
		STATE:			AZ
		ZIP:			85258
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2427383d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:DERM="http://journeymedicalcorp.com/20241104">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_DERM_journeymedicalcorp.com_20241104 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20241104_20241104 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001867066 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000004" name="dei:EntityCentralIndexKey">0001867066</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="derm-20241104.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001867066</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-04</xbrli:startDate>
        <xbrli:endDate>2024-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_908_edei--DocumentType_c20241104__20241104_zhWhL1U8eoIf"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20241104__20241104_zMDnWYvhtNpl"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 4, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20241104__20241104_zcCdwGLKUlai"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000011" name="dei:EntityRegistrantName">Journey Medical Corporation</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20241104__20241104_zpRz2fnyt9j8"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_edei--EntityFileNumber_c20241104__20241104_zLuuWDF5RzK7"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000013" name="dei:EntityFileNumber">001-41063</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20241104__20241104_zIfx4E9W2DGf"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000014" name="dei:EntityTaxIdentificationNumber">47-1879539</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: center">(State or Other Jurisdiction<br/> of Incorporation)</td><td style="font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">(Commission File Number)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-style: normal; font-weight: normal">(I.R.S.
    Employer<br/>
 Identification No.)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20241104__20241104_zovdBgVTNrd"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000015" name="dei:EntityAddressAddressLine1">9237 E Via de Ventura Blvd.</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20241104__20241104_zGEZndiIQs37"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 105</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20241104__20241104_zssZwAEEFhs6"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000017" name="dei:EntityAddressCityOrTown">Scottsdale</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20241104__20241104_zllyYJQGHJB2"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000018" name="dei:EntityAddressStateOrProvince">AZ</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20241104__20241104_zuMi3IL1Igh7"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000019" name="dei:EntityAddressPostalZipCode">8525</ix:nonNumeric></span></b></p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b><span>(<span id="xdx_90A_edei--CityAreaCode_c20241104__20241104_zM8rDBWRf3W8"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000020" name="dei:CityAreaCode">480</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20241104__20241104_zOsmqWWShRC9"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000021" name="dei:LocalPhoneNumber">434-6670</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form
8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span id="xdx_90B_edei--WrittenCommunications_c20241104__20241104_zIAGlKWcBMgj" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_90A_edei--SolicitingMaterial_c20241104__20241104_zjLiHFpi2O0c" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_906_edei--PreCommencementTenderOffer_c20241104__20241104_zz4KsiZHilP6" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20241104__20241104_zIi5SPudabUb" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b>Securities registered
pursuant to Section 12(b) of the Act:</b></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: bottom; width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange<br/>
 on which registered</b></span></td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20241104__20241104_zU1zbc3fUTSh"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000026" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20241104__20241104_zhBZwqgw8cdk"><ix:nonNumeric contextRef="AsOf2024-11-04" id="Fact000027" name="dei:TradingSymbol">DERM</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20241104__20241104_zk24sCAjY4Uh"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Emerging growth company &#160;&#160;<span style="font-family: Wingdings"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20241104__20241104_zYiuapAA8TLh"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_905_edei--EntityExTransitionPeriod_c20241104__20241104_zlVTwAHwXFqk"><ix:nonNumeric contextRef="AsOf2024-11-04" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Wingdings; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Wingdings; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.02.</b></span></td><td><span style="font-size: 10pt"><b>Results of Operations and Financial Condition.</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On November&#160;4, 2024,
Journey Medical Corporation (&#8220;<b>Journey Medical</b>&#8221; or the &#8220;<b>Company</b>&#8221;) announced preliminary estimated
unaudited revenue and selected financial results for the three- and nine-month periods ended September&#160;30, 2024. Journey Medical&#8217;s
consolidated financial statements for these periods are not yet available. These estimates are based on information currently available
to management. Journey Medical&#8217;s actual results are not expected to vary materially from the estimated preliminary results included
herein. The estimates included in this Current Report on Form&#160;8-K have been prepared by, and are the responsibility of management,
and Journey Medical&#8217;s independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures
with respect to the estimates and does not express an opinion or any other form of assurances with respect thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Based on currently available
information, Journey Medical expects to report as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b><i>Three-Month Period
Ended September&#160;30, 2024</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Symbol">&#183;</span></span></td><td>Total net product revenues of $14.6 for the three-month period ended September&#160;30, 2024, compared to $15.3 million for the same
period in 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Symbol">&#183;</span></span></td><td>Gross margin of 63.9% for the three-month period ended September&#160;30, 2024, compared to $59% for the same period in 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Symbol">&#183;</span></span></td><td>Research and Development (&#8220;<b>R&amp;D</b>&#8221;) expenses of $0.8 million for the three-month period ended September&#160;30,
2024, compared to $2.2 million for the same period in 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling, general and administrative (&#8220;<b>SG&amp;A</b>&#8221;) expenses of $11.4 million for the three-month period ended September&#160;30, 2024, compared to $8.6 million for the same period in 2023. Non-cash share-based compensation expense increased by $1.0 million. The remaining increase is primarily due to the expansion of the Company&#8217;s access and coverage platforms and the commencement of the Company&#8217;s launch efforts for Emrosi<sup>TM</sup> (Minocycline Hydrochloride Extended Release Capsules, 40 mg, formerly referred to as &#8220;DFD-29&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) of $(2.4) million for three-month period ended September&#160;30, 2024, compared to net income (loss) of $16.8 million for the three months ended September&#160;30, 2023. The decline in net income period-over-period resulted from, in part, the $19.3 million payment made by Maruho Co.,&#160;Ltd., Journey Medical&#8217;s Japanese license partner (&#8220;<b>Maruho</b>&#8221;), to Journey Medical in connection with the grant by the Company of an exclusive license to Qbrexza in various Asian territories, in August&#160;of 2023 (the &#8220;<b>Maruho License</b>&#8221;).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Symbol">&#183;</span></span></td><td>The Company ended the third quarter of 2024 with $22.5 million in cash.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><b><i>Nine-Month
Period Ended September&#160;30, 2024</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Symbol">&#183;</span></span></td><td>Total net product revenues of $42.5 million for the nine-month period ended September&#160;30, 2024, compared to $44.4 million for
the same period in 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Symbol">&#183;</span></span></td><td>R&amp;D expense of $9.6 million for the nine-month period ended September&#160;30, 2024, compared to $6.0 million for the same period
in 2023. The increase is primarily driven by the $4.1 million filing fee payment to the U.S. Food and Drug Administration (the &#8220;<b>FDA</b>&#8221;)
in January&#160;2024 for DFD-29 and $3.0 million payment for the contractual milestone payment owed to Dr.&#160;Reddy&#8217;s Laboratories,
Ltd (&#8220;<b>DRL</b>&#8221;) triggered by the FDA&#8217;s acceptance of the NDA for DFD-29 in March&#160;2024, offset by lower clinical
development expenses.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Symbol">&#183;</span></span></td><td>SG&amp;A expenses of $30.4 million for the nine-month period ended September&#160;30, 2024, compared to $34.1 million for the same
period in 2023. The decrease is due to the Company&#8217;s continued expense management efforts, offset by non-cash share-based compensation,
the expansion of the Company&#8217;s access and coverage platforms and the commencement of the Company&#8217;s launch efforts for DFD-29.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) of $(16.2) million for nine-month period ended September&#160;30, 2024, compared to net income (loss) of $(1.7) million for the nine months ended September&#160;30, 2023. The decline in net income period-over-period resulted from, in part, the $19.3 million payment made by Maruho to Journey Medical in connection with the Maruho License.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><b><i>Other
Corporate Update</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notification of recovery of cash related to 2021 fraud loss</i></span><span style="font-size: 10pt">. Pursuant to a stipulation and order signed by the Company on September 19, 2024, the United Stated District Court Southern District of New York through the United States Marshalls will be returning approximately $4.4 million of cash, recovered in connection with the previously disclosed September&#160;2021 cybersecurity incident, to the Company. The Company expects to receive the recovered funds in the fourth quarter of 2024.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The information in this
Item 2.02 of this Current Report on Form&#160;8-K is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Form&#160;8-K
shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly
set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Updated Financial guidance for the year ended December 31,
2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Company maintains its 2024 financial guidance of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left">&#8226;</td><td style="text-align: justify">Net product revenue anticipated in the range of $55-$60 million</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left">&#8226;</td><td style="text-align: justify">SG&amp;A expense anticipated in the range of $39-$42 million</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left">&#8226;</td><td style="text-align: justify">R&amp;D expense anticipated in the range of $9-$10 million</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Other Events.</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
November&#160;4, 2024, Journey Medical announced that the FDA has approved Emrosi<sup>TM</sup> (Minocycline Hydrochloride Extended Release
Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed
by Journey Medical in collaboration with DRL. Journey Medical is completing the manufacturing of Emrosi for the U.S. market and anticipates
initial supply will be available in</span> late first quarter or early second quarter of 2025. Journey Medical intends to commercialize
Emrosi in the U.S. with its commercial team.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">As previously disclosed,
Journey Medical obtained global rights for the development and commercialization of Emrosi, other than in certain excluded markets, from
DRL under a license, collaboration, and assignment agreement (the &#8220;<b>DFD-29 Agreement</b>&#8221;). Pursuant to the DFD-29 Agreement,
the Company is contractually obligated to pay DRL contingent regulatory, commercial, and corporate-based milestone payments. The approval
of Emrosi by the FDA on November&#160;4, 2024, triggered a $15.0 million milestone payment obligation to DRL that is due 30 days after
the date of the FDA&#8217;s approval of the product. Additionally, the Company is required to pay royalties on net sales of Emrosi subject
to certain reductions. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of
the related product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Also as previously disclosed,
on December&#160;27, 2023, the Company entered into a Credit Agreement (the &#8220;<b>Credit Agreement</b>&#8221;) with SWK Funding LLC
(&#8220;<b>SWK</b>&#8221;) that originally provided for a term loan facility in the original principal amount of up to $20.0 million.
On July&#160;9, 2024, Journey Medical entered into an amendment to the Credit Agreement with SWK that increased the original principal
amount of the credit facility from $20.0 million to $25.0 million. The $5.0 million of additional principal is contractually required
to be drawn on by Journey Medical upon FDA approval of DFD-29, subject to the receipt of such approval occurring on or before June&#160;30,
2025. Accordingly, the approval of Emrosi by the FDA triggered the Company&#8217;s obligation to draw on the remaining $5.0 million under
the Credit Agreement. The Company intends to draw on the $5.0 million in the fourth quarter of 2024 to fund a portion of the $15 million
milestone payment noted above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On November&#160;4, 2024,
Journey Medical issued a press release announcing the FDA&#8217;s approval of Emrosi a copy of which is attached hereto as Exhibit&#160;99.1
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td><td><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d)&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following exhibits are furnished herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2427383d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2427383d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Journey Medical Corporation, dated November&#160;4, 2024.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
Current Report on Form&#160;8-K may contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities
Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this Current
Report on Form&#160;8-K, the words &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; may refer to Journey
Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs
and any other statements that are not historical facts. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;may,&#8221; &#8220;expect,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;potential&#8221;
and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management&#8217;s
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the
fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result,
may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject
to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor
products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and
we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue
is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating
results; competition could limit our products&#8217; commercial opportunity and profitability, including competition from manufacturers
of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party
payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire
or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business,
including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved
product, Emrosi</span><sup>TM</sup>, and any future product candidates that we may develop, in-license or acquire; clinical drug development
is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of
our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks
related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology
and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our
or our third parties&#8217; cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major
public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional
capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other
risks described in Part&#160;I,&#160;Item 1A, &#8220;Risk Factors,&#8221; in our Annual Report on Form&#160;10-K for the year ended December&#160;31,
2023, subsequent Reports on Form&#160;10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations
or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim
the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Journey Medical Corporation</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <span style="background-color: white">Claude Maraoui</span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claude Maraoui </span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President and Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 4, 2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZF02DLuxOixaxihQRt8FOJdhmyiT+HclbGlvEYWAY3vveEyIWOa1MgwynRVnAAduu0R6hxBoZ7RmDI1tvUgi3xItxnrX1/fsDMwoMBmY6UkoHobfejcMqBTkdy2SsJiBnaTKD+VZEXz0jW5sKrTe6AW0r2DN1bNBrfg0JB/0kS+2rrzoiO0M2hWQkB/kNSiYKdnTXD+Krg6LIRBT3E4mc6dYF1/Lp0X5JWDbYhjo30P+NPgB5SoI= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2427383d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2427383d1_ex99-1img01.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Journey Medical Corporation Announces U.S. FDA
Approval of Emrosi&trade; (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Journey Medical to host investor conference
call on Monday, November 4, 2024, at 8:30 a.m. E.T.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Scottsdale,
AZ &ndash; November 4, 2024</B></FONT> &ndash; Journey Medical Corporation (Nasdaq: DERM) (&ldquo;Journey Medical&rdquo;), a commercial-stage
pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)-approved
prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi<B>&trade;</B>
(Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions
of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy&rsquo;s Laboratories Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Claude Maraoui, Co-Founder, President, and
Chief Executive Officer of Journey Medical, said, &ldquo;With approval from the FDA, Journey Medical is proud to deliver Emrosi, a
unique treatment option for the millions of patients in the U.S. suffering from rosacea. Rosacea is a diffilut to treat skin
condition and based on the favorable results from our Phase 3 clinical trials, Emrosi has potential to become the best-in-class oral
medication to treat the condition. Our seasoned dermatology-focused sales force is now preparing for a successful launch and to
establish Emrosi as a new standard of care in the treatment of rosacea. Journey Medical is committed to bringing cutting-edge
innovation to patients with dermatological conditions and the healthcare professionals who treat them.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The approval of Emrosi is supported by positive
data from Journey Medical&rsquo;s two Phase 3 clinical trials for the treatment of rosacea. The Phase 3 clinical trials met all co-primary
and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues. Emrosi demonstrated statistically
significant superiority over both the current standard-of-care treatment, Oracea&reg; 40 mg capsules, and placebo for Investigator&rsquo;s
Global Assessment treatment success as well as the reduction in total inflammatory lesion count in both studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Journey Medical is completing the manufacturing
of Emrosi for the U.S. market and anticipates that initial supply will be available late in the first quarter or early in the second quarter
of 2025. Journey Medical intends to commercialize Emrosi in the U.S. with its dermatology-focused commercial organization. In line with
the approved label, Journey Medical will execute a launch strategy to drive Emrosi toward becoming a new oral standard of care for adult
rosacea patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Srinivas Sidgiddi, M.D., Vice President, Research
 &amp; Development at Journey Medical, added, &ldquo;Emrosi showed great efficacy and tolerability in the pivotal clinical trials, and
we are tremendously grateful to the patients, physicians, investigators, and site coordinators who participated and contributed to this
important approval milestone.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conference Call and Replay Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Journey Medical management will host a conference
call to review the FDA approval on Monday, November 4, 2024, at 8:30 a.m. Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To listen to the conference call, interested parties
within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 for international callers. All callers should dial in approximately
10 minutes prior to the scheduled start time and ask to be joined into the Journey Medical conference call. Participants can register
for the conference call online by clicking the following link: <U>https://dpregister.com/sreg/10193869/fdcd4e50be</U>. Please note that
registered participants will receive their dial-in number upon registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A replay of the conference call will be available
shortly after the call concludes for approximately two weeks, and can be accessed by dialing 1-877-344-7529 (domestic) or 1-412-317-0088
(international), and providing the replay access code: 8833884. Participants will be required to state their name and company upon registering
for the replay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Safety Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indication: EMROSI&trade; is indicated for the
treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common adverse reaction reported
by &ge;1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia. Contraindications: EMROSI
should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines. Warnings/Precautions: Cases of anaphylaxis,
serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS)
syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized, discontinue EMROSI
immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent
discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated Colitis occurs.
Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should be cautioned about
driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia, and vision loss. Discontinue
EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise. Discontinue EMROSI immediately
if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while using EMROSI. Tetracycline-class
antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes,
thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant bacteria to develop during
the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute appropriate therapy. Perform
periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You are encouraged to report negative
side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For full prescribing information, please visit
<U>www.emrosi.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About
Rosacea</B></FONT><BR>
Rosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like
inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to&nbsp;<U>The National Rosacea Society</U><I>,</I>&nbsp;it
is estimated that rosacea affects well over 16 million Americans and as many as 415 million people worldwide.&nbsp;Rosacea is most frequently
seen in adults between 30 and 50 years of age. Surveys conducted by&nbsp;<U>The National Rosacea Society</U>&nbsp;report that more than
90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had
caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder
had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Journey Medical Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Journey Medical Corporation (Nasdaq: DERM) (&ldquo;Journey
Medical&rdquo;) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription
pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently
markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry
experts with extensive experience in developing and commercializing some of dermatology&rsquo;s most successful prescription brands.
Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical&rsquo;s common
stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and
Exchange Commission (&ldquo;SEC&rdquo;). For additional information about Journey Medical, visit <U>www.journeymedicalcorp.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain
 &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words &ldquo;the
Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo; may refer to Journey Medical. Such statements include, but
are not limited to, any statements relating to our growth strategy and product development programs and any other statements that
are not historical facts. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;may,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;potential&rdquo;
and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on
management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those
currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation
and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales
derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an
increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating
income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative
or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any
setback relating to the sale of such products could impair our operating results; competition could limit our products&rsquo;
commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk
that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties
for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and
integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our
ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved
product, Emrosi<SUP>TM</SUP>, and any future product candidates that we may develop, in-license or acquire; clinical drug
development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety
and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or
identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient
patent protection for our technology and products; our business and operations would suffer in the event of computer system
failures, cyber-attacks, or deficiencies in our or our third parties&rsquo; cybersecurity; the substantial doubt about our ability
to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any
future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock,
which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, &ldquo;Risk
Factors,&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Reports on Form 10-Q, and our
other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions
to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jaclyn Jaffe</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(781) 652-4500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>ir@jmcderm.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Tony Plohoros</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">6 Degrees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(908) 591-2839</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>tplohoros@6degreespr.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: blue"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: blue">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>derm-20241104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaGLqbOdzZR+OYkxtmB3bfn6zygqqaK0VixPLZHGoXsH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:DERM="http://journeymedicalcorp.com/20241104" elementFormDefault="qualified" targetNamespace="http://journeymedicalcorp.com/20241104">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://journeymedicalcorp.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="derm-20241104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="derm-20241104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>derm-20241104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>derm-20241104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://journeymedicalcorp.com/role/Cover" xlink:href="derm-20241104.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://journeymedicalcorp.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2427383d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2427383d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !S /\# 2(  A$! Q$!_\0
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M61Z+_P +27_H$?\ DS_]A1_PM)?^@1_Y,_\ V%><GW%''I1S,+(]&_X6DO\
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=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45365261241856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Journey Medical Corporation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001867066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1879539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9237 E Via de Ventura Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Scottsdale<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AZ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">8525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">434-6670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DERM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI4^@8-;6)5(JJNN'"QJ5H2U5>GE0\QI@W_I91)XE#$1)OFE&S)I![HQM^HA
M787F^5)R_Q)3"8O?X^P <$]>Q^VGC2=JTZ-)S)8@Y-UT( EJ_[5@OV-DFK^A
M+V 5()-\<\TH#$Y[ 9Q?2FF.._:EO_AF,_P74$L#!!0    ( ,8[9%F?H!OP
ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( ,8[9%D'04UB@0   +$    0
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MPPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #&.V19EXJ[',     3 @
M"P              @ &?#P  7W)E;',O+G)E;'-02P$"% ,4    " #&.V19
MJL0B%C,!   B @  #P              @ &($   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ QCMD620>FZ*M    ^ $  !H              ( !Z!$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ QCMD6660
M>9(9 0  SP,  !,              ( !S1(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  %Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2427383d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://journeymedicalcorp.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>derm-20241104.xsd</File>
    <File>derm-20241104_lab.xml</File>
    <File>derm-20241104_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2427383d1_8k.htm">tm2427383d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2427383d1_8k.htm": {
   "nsprefix": "DERM",
   "nsuri": "http://journeymedicalcorp.com/20241104",
   "dts": {
    "schema": {
     "local": [
      "derm-20241104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "derm-20241104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "derm-20241104_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2427383d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://journeymedicalcorp.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2427383d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2427383d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://journeymedicalcorp.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-24-113659-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-113659-xbrl.zip
M4$L#!!0    ( ,8[9%D'<#-]- ,   $,   1    9&5R;2TR,#(T,3$P-"YX
M<V2U5MM2VS 0?>],_T'U*V,[CH&6D,!0*)!I*$Q2*.6EH]B;H&)+CB03AZ^O
MY%LN#B%)6S_)JW/.[FIW93>/DS! S\ %8;1E.%;-0$ ]YA,Z;!FW/?.D=]IN
M&^CXZ/T[I)[F!]-$YP0"OX'.F&>VZ8 =HF\XA :Z  H<2\8/T1T.8FUAYR0
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M +O))@5-34 D6(T!-!RT^3.E7HB8R9%)8#IG,=G]3/9@NUHZMTP -IM0&**
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MHSS>_T8Y_RCD0HPHT5+0I+C5#SWA]Q:!1@%Q#K%"+DH(ODJ>64HJ7PBJ/.>
MQQ2*'''NT",/9^UEL:AY>^TI7N$1(NXK 06/.(D8%HNT/LU0YS-[IN^)(6L/
M0_Q]):#\$2<4PV+1UL^KOKWP3&5XSOS $$H;<2ELJ304R*.4<'Z=:2:H#HXM
M!X90R(AK7DNEH4"^2:F:VD'M@Y(+,UOO[0S!]A2 0D=<V1J4B@-_^6,?>;'_
M+4B^Q!K\=@)$[%Z16*_=B&.WD**XDHN$* _UD#V4.^K&2K_0FLG?F1E5N_=/
MN3-#F[>%%CU4EX)& 25=A8K&N;;N[.0/7EKW[*"\$1/3,F$X>Z:R,6?Q@$L2
MO"_?,X/R1<Q"2V2AX+TFXDEE<Q.O[I6,*773)WI[M@$2(F %T) @YJ<O0H'S
MN$"FJ=M,)..GT<R*UG>9R=]H:OT+/C0(EH.&!G,3)T XTEV0_K'1BR;7JP<Z
MH<HM4WBD2W-M&WH*WQ0!BD/C@_I&(3"&DC!=M(]TW=H#[IVUQ3?NEWLOJSWR
M/U!+ P04    " #&.V19.TIE[0XE  !TP@  $@   '1M,C0R-S,X,V0Q7SAK
M+FAT;>T]:7?;MK+?^2OX]-)[G5-)UN8]T3NR92=.O*264R?YXD.1D,2$(ADN
MEI1?_V8& #>1DKS&:=/3UC8) C.#F<%L %[]WW1LJ3?,\TW'?OW?>K7V7Y79
MNF.8]O#U?SN]@^/C__Y?6WDU"J 9-+7]UZ51$+B[Z^N3R:0Z:58=;[A>W]G9
M69]BFQ)OM#O-;=>HU>KKGTY/>OJ(C;6*:?N!9NLL^L@R[6_%_>/;J&G?L\Q4
M4WPB!VFNSW4-;XWX@V3CS77^,M4TR&VZP9L&LJGI.ZU&?6L1'+Q%],&TJ&T=
M808,V:?]BY.X>9#?/FZZ'GB:[0\<;ZP%,(78TT:EUJ@T-A.=5'RFISJ"OZM#
MYV9I/]N59EWV,S<Y:4SQ=5_S(XH;+$-N.2:\@"\:3=DP]"M#37.CQ@/-[U.W
MXD6VL>=8S,]M36]2S74GM -OE@^(>)GZP/>"^:[A8:I1]_#B-&KUU0D]F\W&
MS#!US=(=SZWJSAC;M^KU6JN$PL,THZVH^,^KP PLUGZUSG\JK\8LT%3LJL*^
MA^;-Z]*!8P?,#BJ7,Q=HJ?._7I<"-@W62<+6X:MUWN6K_ZE4U".36<:NVF/!
MGGJFC=FN.C6F>^IQEWZYKC4.KC_V_FATWW0Z'^ '(J)6*BM^W.Q<([;7^5A>
M2RQ7[[!U%'UTAZ\W=JX9\ ^@ ?]VQLPVX+_@R-*&UP/-\MDM>MI/]'1HPW3,
M#J K3[..;8--W[/9=0VTU?;F5FUS<_5N-_>!V-WK^K40?-X_/+I%%XWKWDCS
MF'_=N"8UQ_OPZ=DMNNDB)!]$5\TY@(KZ[CO&3/6#F<5>EP; ?;MJO>8&ZJ4Y
MAA9G;*)>.&/-+O,'91C?,P?(Y(9Y(S\S3-^UM-FN:CLVPW?F=!<9EGD@!?2'
M:1C,1I' OZ#563B&?G3.[M/@@@U>ESK^^0 YI%*O5T".5--X73K2]*"&_X L
MVH TC,7,W10CE-K$":_64SW?9ZQ6<JQ<5BFU8U[)&W@]B3."X;$!\V"=93Z]
M1]VYZ].B"."HM-+MCCR$#(@VKDA!J4Y]HR1>!Z ?7I=\<^Q:#'6"&";5,Q_*
M!]D5(T$CFO9=@3PAFD%>:"K9DA'"\F'TV#3PQ<!DGDJ L]SUY>#X?9HVV8^C
MP=;S1A-CN4!(QY@# 59X+^AJ 6O'T,M^XG?9KX!5"KZ1;S(@)4>7SP3Y4B0-
M;9/3$X0K2\0QT_S08VTAA+O01'8E7Z7ZQ[[R.^?R7-2_0)[:W'& 6&ED!P$)
MAXF;(RA^2<RN!8X7O[TU[EGP<OI,C-AEMC,V[25C+J5'=M"<;N7K)/I9,@K1
MBR6-B[S0>:_6X=NVHBBO7*DBQYHW-.U=M58"6\"%=TF=?A%:K/)!&])REE2L
M_*M*X+CPI0N*7SSH.T'@C,6SB6D$(]3:M3]*J:_[C@?@\*_W+4W_IC9 L?N.
M91I[JG@I>^+OZ_%[7 HJOOD#UAEX6FK_YW_KF[4]CIGX?P*#]10*!8C++MQ4
M ['F;"];<R3RA+5:VU-1("N:90[AD0YZA'F ?K_]\>SX\K"K]BX[EX>]5^O]
M]F,/V#L\^'AQ?'E\V%,[9UWU\-/!V\[9FT/UX/ST]+C7.SX_6P#%TJ5V52BN
M.KVWQV=O+L_/RFJW>E!5&[6-UL[]1IX?*N+ 12RY9*8?<V ^9'+0>2'(,/DS
M)T5J]DN/SLQ'YQ>GZBO?U6Q:'-"RW*EMD^E<J70=/42S"UV5:STRZV,#_\?H
M:G12_[C-G&.P$>]J?^TD[:_DF*7V=N5]UMYZM8[0MO,X?14=]\RG_WGP72&[
M@.:[.#R[5"\./YQ?7#ZZGGL:I#Z$GA]J=J &#GRH8WA$K3=5QU/K&VO&2]49
MJ,&(*? J],S A $/I_I(LV'QZ^@!OJ[O-%L/2(PG01Q-883]@KF.%ZAK\F^F
M@>'#_$!E-]!2]>@U,U[NSJF)3D9-?"!#^I!;V?GZXK1K7WV^&05GKG4K?<'C
M5J]+YC38-:#W,;0=&=IL!M R.ZU/ZK4\?9("KM0^<V[8N _.3:NLXD"%6N8I
M)O3!M'EVAO;%#'&G]H(-31_#@ '&$_(G2#\P)F].WG^T-//."KU>GW>HTV.7
MVN]XO$D]Y0$G]<#Q@,\H-'D+A?^@ K%V. 4$*-;"Y4)"K&J^VG.9C@ZMH9JV
M>@#^!GSR\G&X(]#Z%@.H+,O5#(K3EX"C\6^@@R[_OO608G'4'<O27!_,?/E;
MQJ- ;R?P9/\WS MP@B2Q^)H#O<'2.O2<T#:P1\?;5:]&)@H6=Y\"8]4U68S=
M;/R1]D%HH:,'$V8.1P$.;1D%G+^0[8]M/6:N7@#B?\ #PP>.42 %[L6/QL">
M!3M?M^^JIC DCU&*@+F><X/B,*>G&O-BLA!6T-G,TB:@\0I%)##:"=H+_HF(
M7T^XCZO1.V;-P'@64WN4FMHCTV)  ]#C^?-X$H97W:.-BQ_OM^ZNS9KSTQ2/
MB]&O>J55KVTV_[V34D]-RJ4V/1;Q/YWX>-$,'0^FK<.=JT;WS=T=B'I. +<
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MI3 .@CNDA'!_EE0[%/)!C:E;H8_K@!P=NOVK[['I#PV[NP&-Z(2^VO%-:!V
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M[^U 0^J:"OH\H]"))0A9N$*0U@#9RZJ"_6AF(+;CZ:*'MS6AC2M3F\ME"=1
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M+GAS9%!+ 0(4 Q0    ( ,8[9%G4I4R;_@H  ("&   5              "
M 6,#  !D97)M+3(P,C0Q,3 T7VQA8BYX;6Q02P$"% ,4    " #&.V19O9H%
M<& '  #I5P  %0              @ &4#@  9&5R;2TR,#(T,3$P-%]P<F4N
M>&UL4$L! A0#%     @ QCMD63M*9>T.)0  =,(  !(              ( !
M)Q8  '1M,C0R-S,X,V0Q7SAK+FAT;5!+ 0(4 Q0    ( ,8[9%D4&=44,A@
M -9.   6              "  64[  !T;3(T,C<S.#-D,5]E>#DY+3$N:'1M
64$L%!@     %  4 20$  ,M3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2427383d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="derm-20241104.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001867066</identifier>
        </entity>
        <period>
            <startDate>2024-11-04</startDate>
            <endDate>2024-11-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-04" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-04" id="Fact000004">0001867066</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-04" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-04" id="Fact000010">2024-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-04" id="Fact000011">Journey Medical Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-04" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-04" id="Fact000013">001-41063</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-04" id="Fact000014">47-1879539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-04" id="Fact000015">9237 E Via de Ventura Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-11-04" id="Fact000016">Suite 105</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-04" id="Fact000017">Scottsdale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-04" id="Fact000018">AZ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-04" id="Fact000019">8525</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-04" id="Fact000020">480</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-04" id="Fact000021">434-6670</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-04" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-04" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-04" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-04" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-04" id="Fact000026">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-04" id="Fact000027">DERM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-04" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-04" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2024-11-04" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
